Pharm-Olam is now Allucent. Learn More

Request a Proposal  

By: Admin on February 12th, 2015

Print/Save as PDF

Pharm-Olam: Phase III Pulmonary Arterial Hypertension study completed

Pharm-Olam was selected to provide development services for a Phase III study, which was designed to address the efficacy and safety for a compound for pulmonary arterial hypertension patients.

Pharm-Olam was responsible for:
  • The recruitment of 192 patients
  • Management of 17 sites in Russia, Belarus, and Ukraine
  • All regulatory, project management, and monitoring services

To view the case study and the lessons learned in this study, click here